共 50 条
- [1] Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical StudyBLOOD, 2016, 128 (22)Awan, Farrukh T.Schuh, AnnaBrown, Jennifer R.Furman, Richard R.Pagel, John M.Hillmen, PeterStephens, Deborah M.Hamdy, AhmedHuang, JaneIzumi, RaquelPatel, PritiWang, Min HuiByrd, John C.
- [2] Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical StudyBLOOD, 2016, 128 (22)Hillmen, PeterSchuh, AnnaEyre, Toby A.Pagel, John M.Brown, Jennifer R.Ghia, PaoloAllan, John N.Wierda, WilliamHamdy, AhmedHuang, JaneIzumi, RaquelPatel, PritiWang, Min HuiByrd, John C.
- [4] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 StudyBLOOD, 2017, 130Byrd, John C.Wierda, William G.Schuh, AnnaDevereux, StephenChaves, Jorge M.Brown, Jennifer R.Hillmen, PeterMartin, PeterAwan, Farrukh T.Stephens, Deborah M.Ghia, PaoloBarrientos, Jacqueline C.Pagel, John M.Woyach, Jennifer A.Charuworn, PristaHamdy, AhmedIzumi, RaquelPatel, PritiRothbaum, Wayne M.Wang, Min HuiFurman, Richard R.
- [5] Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 StudyBLOOD, 2018, 132Byrd, John C.Woyach, Jennifer A.Furman, Richard R.Martin, PeterO'Brien, Susan M.Brown, Jennifer R.Stephens, Deborah M.Barrientos, Jacqueline C.Devereux, StephenHillmen, PeterPagel, John M.Chen, Dih-YihHamdy, AhmedIzumi, RaquelPatel, PritiWang, Min HuiJain, NitinWierda, William G.
- [6] Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S283 - S283Byrd, John C.Woyach, Jennifer A.Furman, Richard R.Martin, PeterO'Brien, SusanBrown, Jennifer R.Stephens, Deborah M.Barrientos, Jacqueline C.Devereux, StephenHillmen, PeterPagel, John M.Chen, Dih-YihHamdy, AhmedIzumi, RaquelPatel, PritiWang, Min HuiJain, NitinWierda, William G.
- [7] Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/ Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1 /2 ACE-CL-001 StudyBLOOD, 2017, 130Covey, ToddGulranjani, MichaelCheung, JeanBibikova, ElenaClevenger, TracyKrantz, FannyPan, KarenYamaguchi, KyokoDe Jong, AnoukVan Lith, BartMittag, DianaIzumi, RaquelByrd, John C.Wierda, William G.O'Brien, Susan M.Furman, Richard R.Kaptein, Allard
- [8] Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 studyLANCET HAEMATOLOGY, 2021, 8 (12): : E912 - E921Eyre, Toby A.Schuh, AnnaWierda, William G.Brown, Jennifer R.Ghia, PaoloPagel, John M.Furman, Richard R.Cheung, JeanHamdy, AhmedIzumi, RaquelPatel, PritiWang, Min HuiXu, YanByrd, John C.Hillmen, Peter
- [9] Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 StudyBLOOD, 2017, 130Wang, MichaelRule, SimonZinzani, Pier LuigiGoy, AndreCasasnovas, Rene-OlivierSmith, Stephen D.Damaj, GandhiDoorduijn, Jeanette K.Lamy, ThierryMorschhauser, FranckPanizo, CarlosShah, BijalDavies, AndrewEek, RichardDupuis, JehanJacobsen, EricKater, Arnon P.Le Gouill, StevenOberic, LucieRobak, TadeuszCovey, ToddDua, RichaHamdy, AhmedHuang, XinIzumi, RaquelPatel, PritiSlatter, J. GregJurczak, Wojciech
- [10] Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 resultsBLOOD, 2020, 135 (15) : 1204 - 1213Byrd, John C.Wierda, William G.Schuh, AnnaDevereux, StephenChaves, Jorge M.Brown, Jennifer R.Hillmen, PeterMartin, PeterAwan, Farrukh T.Stephens, Deborah M.Ghia, PaoloBarrientos, JacquelinePagel, John M.Woyach, Jennifer A.Burke, KathleenCovey, ToddGulrajani, MichaelHamdy, AhmedIzumi, RaquelFrigault, Melanie M.Patel, PritiRothbaum, WayneWang, Min HuiO'Brien, SusanFurman, Richard R.